GenoMed's Novel Treatment Working for Post-West Nile Virus Encephalitis Syndrome
Friday June 18, 9:35 am ET
ST. LOUIS, June 18 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation DM(TM) (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today that its unique, patent-pending approach to West Nile virus encephalitis appears to work even months after the acute episode.
Some people with West Nile virus encephalitis fail to recover completely even long after the acute episode. They may have headache, continued paralysis, weakness, fatigue, or tremors. Such residual symptoms are called post-West Nile virus encephalitis syndrome. West Nile virus is not the only virus which can cause them. Polio can do the same thing.
GenoMed has now seen gratifying responses in two patients with post-WNV encephalitis syndrome. One patient had constant headaches for seven months after her episode of WNV encephalitis last summer. Her headaches disappeared within a week of starting GenoMed's experimental approach. A second patient, Mr. Thomas Cook, began GenoMed's treatment two months after West Nile virus encephalitis, when he was still paralyzed in his right leg. His story appeared yesterday on WCVB Channel 5, Boston at:
thebostonchannel.com
GenoMed's goal is to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S.
For more information, click on the "West Nile trial" link at genomedics.com .
About GenoMed
GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is currently marketing its protocol for preventing kidney failure due to high blood pressure and diabetes, and delaying emphysema. Next summer it will begin charging a modest license fee for the use of its West Nile virus treatment protocol.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our treatment for West Nile virus encephalitis will remain effective for larger numbers of patients; (b) whether our server holds up to heavy demand; (c) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
biz.yahoo.com |
